Advertisement

Existing antiviral drugs may be key to treating novel coronavirus: Study

Follow The Hawk on Google News+ Follow

Advertisement


London: Already approved broad-spectrum antiviral drugs may offer a first-line treatment for the novel coronavirus which has so far killed over 2,700 people and infected around 80,000, according to a study unveiled on Thursday. Researchers from the Norwegian University of Science and Technology (NTNU) noted that there is no vaccine or cure for the virus in sight.

This means that doctors can do little more than offer supportive treatment to the very sick, and hope their bodies can survive the infection, they said.

Advertisement

According to the study, published as a pre-proof in the International Journal of Infectious Diseases, already approved drugs might hold the key to treating the new virus.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

"Drug repurposing is a strategy for generating additional value from an existing drug by targeting diseases other than that for which it was originally intended," said Denis Kainov, an associate professor at NTNU.

"For example, teicoplanin, oritavancin, dalbavancin and monensin are approved antibiotics that have been shown to inhibit corona- and other viruses in the laboratory," Kainov said.

Advertisement

The researchers said these and other already tested "safe-in-man" broad-spectrum antiviral drugs are good candidates for treating the disease to start with, given that there are currently no treatments for the new coronavirus.

Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead

According to the World Health Organization (WHO), the virus called COVID-19 can cause mild symptoms including a runny nose, sore throat, cough, and fever.

It can be more severe for some persons and can lead to pneumonia or breathing difficulties.

The researchers noted that the advantage of repurposing a drug is that all of the details surrounding the drug development are already known.

These include the chemical synthesis steps, manufacturing processes, and information regarding the different phases of clinical testing.

"Repositioning of launched or even failed drugs to viral diseases provides unique translational opportunities, including a substantially higher probability of success to market as compared with developing new virus-specific drugs and vaccines," the researchers said.

It also offers significantly reduced cost and timeline to clinical availability, they said.

The researchers reviewed information on the discovery and development of broad-spectrum antiviral agents (BSAAs), which are drugs that target viruses from two or more different viral families.

They summarised what they found for 120 drugs that had already been shown to be safe for human use and created a database.

Thirty-one of these were found by the researchers to be possible candidates for prophylaxis and treatment of the COVID-19 infections.

The researchers also found that clinical investigations have recently begun of five possible drug candidates to treat the COVID-19 virus.

—PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST